Replies to post #36777 on RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

Another more specific point to the Cortex brass if anybody's listening. The most likely partner for Cortex is Servier based on clinical emphasis and sustained, undiluted interest in the ampakine platform. Others come and go(or are bought and refocus their attention elsewhere), but Servier has been interested in Cortex. We all know the Cortex-Servier partnership ended on less than stellar terms as Cortex --via Stoll's negotiations-- acquired North American rights for neurodegneration for high inpact compounds. But at what cost? Will Servier sign a deal with Cortex while the current management team is in place? Was the brilliance at Stoll a few years back in outsmarting the French critical in Servier keeping a legal respect for the original deal but making it colder in hell for them to ink a deal with Cortex, and would a change in management team lead to a deal with Cortex. I don't pretend to have the answer for this question, but I have a strong hunch Servier may find it hard to stomach inking a new deal with Cortex while certain members of the current management team remain in place.